Spots Global Cancer Trial Database for mast cell leukemia
Every month we try and update this database with for mast cell leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia | NCT00782067 | Leukemia | Midostaurin (PK... | 18 Years - | Novartis | |
| Managed Access Programs for PKC412, Midostaurin | NCT05219266 | FMS-Like Tyrosi... Acute Myeloid L... Aggressive Syst... Mast Cell Leuke... Systemic Mastoc... | midostaurin | 18 Years - | Novartis | |
| Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | NCT00898079 | Acute Undiffere... Atypical Chroni... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Solid... Chronic Lymphoc... Hairy Cell Leuk... Juvenile Myelom... Mast Cell Leuke... Neoplasm of Unc... Prolymphocytic ... Secondary Acute... T-Cell Large Gr... | Cytology Specim... | - 30 Years | Children's Oncology Group | |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | NCT00493129 | Leukemia Systemic Mastoc... | Ontak (Denileuk... | - | M.D. Anderson Cancer Center | |
| (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | NCT02561988 | Aggressive Syst... Systemic Mastoc... Mast Cell Leuke... Relapsed or Ref... | Avapritinib | 18 Years - | Blueprint Medicines Corporation | |
| Mast Cell Connect: A Registry for Patients With Mastocytosis | NCT02620254 | Mastocytosis | - | Blueprint Medicines Corporation | ||
| Mast Cell Connect: A Registry for Patients With Mastocytosis | NCT02620254 | Mastocytosis | - | Blueprint Medicines Corporation | ||
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | NCT03214666 | High-risk Myelo... Acute Myelogeno... Systemic Mastoc... Mast Cell Leuke... | GTB-3550 TriKE®... GTB-3550 TriKE®... | 18 Years - | GT Biopharma, Inc. | |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | NCT04996875 | Advanced System... SM With an Asso... Mast Cell Leuke... Aggressive Syst... | bezuclastinib | 18 Years - | Cogent Biosciences, Inc. | |
| Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM | NCT04695431 | Advanced System... Aggressive Syst... Systemic Mastoc... Mast Cell Leuke... | 18 Years - | Blueprint Medicines Corporation | ||
| Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial | NCT00890435 | Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi... | questionnaire a... psychosocial as... | 18 Years - | Children's Oncology Group | |
| Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial | NCT00890435 | Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi... | questionnaire a... psychosocial as... | 18 Years - | Children's Oncology Group | |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis | NCT00387426 | Accelerated Pha... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Atypical Chroni... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Mast Cell Leuke... Meningeal Chron... Primary Myelofi... Progressive Hai... Prolymphocytic ... Recurrent Adult... Recurrent Adult... Refractory Chro... Refractory Hair... Relapsing Chron... Secondary Acute... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... T-cell Large Gr... Untreated Adult... Untreated Adult... Untreated Hairy... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | NCT00493129 | Leukemia Systemic Mastoc... | Ontak (Denileuk... | - | M.D. Anderson Cancer Center | |
| Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | NCT01807598 | Aggressive Syst... Mast Cell Leuke... Systemic Mastoc... | Brentuximab ved... | 18 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
